axitinib

Tracon Has Started Dosing in a Phase Ib Clinical of TRC105 for The Treatment of Patients
Sep 25, 2013
US-based biopharmaceutical firm Tracon Pharmaceuticals has started dosing in a Phase Ib clinical of TRC105 for the treatment of patients with metastatic renal cell carcinoma. The trial evaluates the combination of TRC105 and a standard ...

Tags: Tracon, Carcinoma Drug
The European Commission Will Review CHMP's Positive Opinion
Dec 4, 2012
Pfizer has received positive opinion from the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency for the marketing authorization of axitinib to treat patients with advanced renal cell carcinoma. The European ...

Tags: Pfizer, axitinib, advanced renal cell carcinoma
EC Has Granted Marketing Authorization to Pfizer's INLYTA (Axitinib) Oral Therapy
Dec 4, 2012
The European Commission (EC) has granted marketing authorization to Pfizer's INLYTA (axitinib) oral therapy, designed to treat adult patients with advanced renal cell carcinoma (RCC). INLYTA, a kinase inhibitor, is designed to ...

Tags: European Marketing Authorization, INLYTA Oral Therapy